

CURRICULUM VITAE

Peter Albers, MD

Professor and Chairman
Department of Urology, Heinrich-Heine University Düsseldorf
Moorenstr. 5, D-40225 Düsseldorf, Germany



born: October 7, 1963
in: Nürnberg / Germany

Professional Data

1982-1988	Medical School at Universities Aachen and Mainz
1988-1996	Surgical Training and Urological Residency at Universities Mainz and Bonn (Prof. Dr. R. Hohenfellner, Prof. Dr. S. C. Müller)
1996-1998	Staff at the Department of Urology, Bonn University
1998-2003	Vice Chairman of the Department of Urology, Bonn University
2003-2008	Chairman, Department of Urology, Klinikum Kassel GmbH, Marburg University
since 08/2008	Professor and Chairman, Department of Urology, Heinrich-Heine-University Düsseldorf

1993 - 1994	Research Fellowship at Indiana University, Indianapolis, USA, Dept. of Urology (Prof. J. P. Donohue) and at the Department of "Cancer Research" Eli Lilly, Inc., Indianapolis, USA (Grant of the German Research Foundation, DFG AL 391/1-3.1)
04/1996	Board Certification Urology, Bonn University
06/1997	Habilitation (Thesis for Associate Professorship) "Prognostic Parameters in Low-Stage Testis Cancer"

CURRICULUM VITAE

- 09-12/1998 Clinical Observership Pediatric Urology at the Riley Hospital for Children Indianapolis, Indiana University, Indianapolis, USA, Department of Pediatric Urology (Prof. R. C. Rink) and at the Children´s Hospital of Philadelphia, Department of Pediatric Urology (Prof. D. A. Canning) and Urologic Oncology at the Memorial Sloan Kettering Cancer Center, New York City, USA (Prof. P. T. Scardino)
- 07/2002 Professor of Urology, Bonn University
-

Publications

- > 330 original papers (peer-reviewed) mainly in urologic oncology
- > h-Index 47, citations 6084 (Scopus)
- > 25 review articles, 2 books as editor in chief

Memberships

German Association of Urology (DGU), American Urological Association (AUA), European Association of Urology (EAU), German Cancer Society (DKG), American Society of Clinical Oncology (ASCO), European Organization for Research and Treatment of Cancer (EORTC)

- Co-Chairman Advanced Bladder Cancer DOG GU Group EORTC 2010 - 2016
- Chairman Association of Urological Oncology (Clinical Trials Group) 2004-2010
- Executive Board Member German Cancer Society since 2010
- Member, Scientific Office (Video Committee) EAU 2000-2012
- Chairman EAU Testis Cancer Guidelines Group 2006-2018
- President German Cancer Congress 2012
- Vice President of the German Cancer Society (since 2012)

CURRICULUM VITAE

- Member of the Scientific Congress Office (SCO) of the European Association of Urology (EAU) (since 2012)
- Member of the Scientific Program Committee of the American Society of Clinical Oncology (ASCO) (2013-2016)
- President of the German Cancer Society (2016-2018)

Clinical Interests

- Robotic Surgery in Uro-Oncology (cystectomy, radical prostatectomy, partial nephrectomy, reconstructions)
- Postchemotherapy retroperitoneal lymph node dissections
- Reconstructive Urology (urethroplasties, continent diversions, penile prosthesis)
- General Urology (Holmium laser treatment BPH and stones including endourology)

Scientific Interests

- Bladder cancer clonal evolution
- Prostate cancer screening (www.probase.de)
- mpMRI prostate cancer
- testis cancer pathogenesis and prognosis

Visiting Professorships

- 2011 University of Toronto, Princess-Margaret-Hospital, Canada
- 2012 University of Indianapolis, Indiana, USA
- 2013 University of Leiden and Erasmus University, Rotterdam, The Netherlands
- 2017 University of Seattle - Virginia Mason Cancer Center, Seattle, USA
- 2018 University of Milan, San Raffaele Hospital, Vita Salute, Italy

CURRICULUM VITAE

Ten most important publications

- 1: Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. *Eur Urol.* 2018 Aug 3. pii: S0302-2838(18)30553-0. doi:10.1016/j.eururo.2018.07.031. [Epub ahead of print] PubMed PMID: 30082150.
- 2: Niegisch G, Nini A, Michalski R, Henn A, Mally D, Albers P, Rabenalt R. Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion. *Urol Int.* 2018 Jul 25:1-8. doi: 10.1159/000491588. [Epub ahead of print] PubMed PMID: 30045033.
- 3: Nini A, Konieczny M, Winter C, Lusch A, Krauspe R, Albers P. Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. *Urol Oncol.* 2018 Feb;36(2):82.e1-82.e5. doi: 10.1016/j.urolonc.2017.10.016. Epub 2017 Nov 10. PubMed PMID: 29129354.
- 4: Boormans JL, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes MP, Bokemeyer C, Nicolai N, Algaba F, Oldenburg J, Albers P. Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. *Eur Urol.* 2017 Nov 20. pii: S0302-2838(17)30826-6. doi: 10.1016/j.eururo.2017.09.025. [Epub ahead of print] Review. PubMed PMID: 29100813.
- 5: Flechtner HH, Fischer F, Albers P, Hartmann M, Siener R; German Testicular Cancer Study Group. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. *Eur Urol.* 2016 Mar;69(3):518-25
- 6: Arsov C, Rabenalt R, Blondin D, Quentin M, Hiester A, Godehardt E, Gabbert HE, Becker N, Antoch G, Albers P, Schimmöller L. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. *Eur Urol.* 2015 Oct;68(4):713-20
- 7: Winter C, Pfister D, Busch J, Bingöl C, Ranft U, Schrader M, Dieckmann KP, Heidenreich A, Albers P. Residual Tumor Size and IGCCCG Risk Classification Predict Additional Vascular Procedures in Patients with Germ Cell Tumors and Residual Tumor Resection: A Multicenter Analysis of the German Testicular Cancer Study Group. *Eur Urol.* 2011 Nov 7. [Epub ahead of print]
- 8: Heidenreich A, Pfister D, Witthuhn R, Thüer D, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. *Eur Urol.* 2009 Jan;55(1):217-24
- 9: Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M; German Testicular Cancer Study Group. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. *J Clin Oncol.* 2008 Jun 20;26(18):2966-72
- 10: Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M; AUO-AB 05/95. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally

CURRICULUM VITAE

advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol. 2005 Aug 1;23(22):4963-74